Zobrazeno 1 - 10
of 271
pro vyhledávání: ''
Publikováno v:
Journal of Human Genetics
Breast cancer is a heterogeneous disease that develops through a multistep process via the accumulation of genetic/epigenetic alterations in various cancer-related genes. Current treatment options for breast cancer patients include surgery, radiother
Autor:
María Teresa Sánchez-Barrón, Ana I. Álvarez-Mercado, Carmen M Ruiz-Marín, Cándido Robles-Sánchez, Saturnino Reyes Lartategui, María José Sáez-Lara, María Belén Sánchez-Andujar, Mariana F. Fernández, Alejandro J. Pérez-Alonso, Ana Moreno-Delgado, Tania Gallart-Aragón, Natalia Chueca, Katia Torres-Martínez, Julio Plaza-Díaz, Federico García, Iris Reina-Pérez, Luis Fontana, Pablo Torné
Publikováno v:
Digibug. Repositorio Institucional de la Universidad de Granada
instname
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
instname
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Cancer
We would like to thank M Luisa Puertas-Martin and Isabel Manzano-Jimenez, nurses at the Unit of Mammary Pathology, General Surgery Service, San Cecilio University Hospital (Granada), without whose enthusiasm the enrolment of participants in Granada w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8509963333b0ca31ea8159ad28a282
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Liisa M. Pelttari, Paula Poikonen-Saksela, Kristiina Aittomäki, Päivi Auvinen, Arja Jukkola-Vuorinen, Sanna Hallamies, Heli Nevanlinna, Johanna Mattson, Carl Blomqvist, Antti Jekunen
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017)
BMC Cancer
BMC Cancer
Background Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4819e7805611ab5361165ecad3b1625
https://erepo.uef.fi/handle/123456789/5171
https://erepo.uef.fi/handle/123456789/5171
Autor:
Jan Steffen, Michalina Dabrowska, Aneta Balabas, Magdalena Piatkowska, Dorota Nowakowska, Izabela Brozek, Anna Niwińska, Magdalena Ratajska, Jadwiga Rachtan, Janusz Limon, Anna Kluska
Publikováno v:
Familial Cancer
It is estimated that about 5–10% of ovarian and 2–5% of all breast cancer patients are carriers of a germline BRCA1 or BRCA2 gene mutation. Most families with detected BRCA1 or BRCA2 gene mutation are qualified for molecular testing on the basis
Autor:
Magda A Blaut, Thilo Dörk, Michael Bremer, Natalia Bogdanova, Evgeny N. Imyanitov, Hans Christiansen, Aglaya G. Iyevleva, Svetlana N. Abysheva, Anna P. Sokolenko, Margret Rave-Fränk
Publikováno v:
Breast Cancer Research and Treatment
Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Pat
Autor:
Italia Bongarzone, Vera Cappelletti, Maurizio Callari, Maria Grazia Daidone, Valeria Musella, Silvia Veneroni, Barbara Valeri, Loris De Cecco, Marco A. Pierotti
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 409 (2009)
BMC Cancer, Vol 9, Iss 1, p 409 (2009)
Background Gene expression profiling is moving from the research setting to the practical clinical use. Gene signatures able to correctly identify high risk breast cancer patients as well as to predict response to treatment are currently under intens
Autor:
Qingwei Luo, Roberta De Angelis, Nehmat Houssami, Dianne L. O'Connell, Xue Qin Yu, Clare Kahn
Publikováno v:
BMC Cancer
Background Breast cancer places a heavy burden on the Australian healthcare system, but information about the actual number of women living with breast cancer and their current or future health service needs is limited. We used existing population-ba
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
BMC Cancer
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial c